leadf
logo-loader
viewOxford BioMedica plc

Oxford Biomedica secures third partnership in CAR-T field

NASDAQ-listed Beam Therapeutics signed up to use the firm's LentiVector platform in its projects

Oxford BioMedica plc - Oxford Biomedica secures third partnership in CAR-T field

Oxford Biomedica plc (LON:OXB) announced an agreement to licence its LentiVector platform to NASDAQ-listed Beam Therapeutics.

Beam will use apply the suite of technologies to its CAR-T programmes in oncology, which engineer the patient’s cells to target tumours.

FTSE 250-listed Oxford Biomedica will receive an undisclosed upfront payment, payments related to lentiviral vectors for use in clinical trials, plus development and regulatory milestones alongside an undisclosed royalty on the net sales of the final products.

The pair are also working on a pre-clinical programme.

It is Oxford Biomedica’s announced partnership with developers in the CAR-T field, after Novartis and Bristol Myers Squibb.

“We see it as further confirmation after last week’s new three-year clinical supply agreement with Axovant that OXB’s underlying business continues to develop apace,” analysts at house broker Peel Hunt commented.

“The addition of a new partner, with potential to add multiple further projects in one of OXB’s core areas of expertise – CAR-T – is also a clear positive.”

Shares added 1% to 828.1p on Monday at the opening bell.

Quick facts: Oxford BioMedica plc

Price: 830 GBX

AIM:OXB
Market: AIM
Market Cap: £681.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Learning Technologies Group reports 'robust and resilient performance' for...

Learning Technologies Group's (LON:LTG) Jonathan Satchell says its half year results to June 2020 were 'robust and resilient'. The six month period saw an increase in underlying adjusted earnings before interest and tax (EBIT) to £20.1m (excluding non-cash items) from £19.4m the year...

26 minutes ago

2 min read